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Elevated plasma homocysteine levels are associated with increased risk of fractures in 3 
observational studies. However, it is unsettled if homocysteine-lowering treatment affects 4 
fracture risk. The aim of this study was to investigate the effect of an intervention with B-5 
vitamins on the risk of hip fracture in a secondary analysis of combined data from two large 6 
randomized controlled trials originally designed to study cardiovascular diseases. Both trials 7 
had identical design, intervention and primary objective. Based on a 2x2 factorial design, the 8 
intervention consisted of a daily capsule with either 1) folic acid (0.8 mg) plus vitamin B12 9 
(0.4 mg) and vitamin B6 (40 mg) or 2) folic acid (0.8 mg) plus vitamin B12 (0.4 mg) or 3) 10 
vitamin B6 alone (40 mg) or 4) placebo. The participants were followed with respect to hip 11 
fracture during the trial or during an extended follow-up (from the trial start for each patient 12 
until the end of 2012). No statistically significant association was found between folic acid 13 
plus vitamin B12 treatment and the risk of hip fracture, neither during the trial (median 3.3 14 
years; hazard ratio (HR) 0.87; 95% CI 0.48-1.59) nor during the extended follow-up (median 15 
11,1 years; HR 1.08; 95% CI 0.84-1.40). Nor were there significant differences in the risk of 16 
hip fracture between groups receiving vs. not receiving vitamin B6 during the trial (HR, 1.42; 17 
95% CI 0,78-2,61). However, during the extended follow-up those receiving vitamin B6 18 
showed a significant 42% higher risk of hip fracture (HR, 1.42; 95% CI 1.09-1.83) compared 19 
to those not receiving vitamin B6. In conclusion, treatment with folic acid plus vitamin B12 20 
was not associated with the risk of hip fracture. Treatment with high dose of vitamin B6 was 21 
associated with a slightly increased risk of hip fracture during the extended follow-up (in-trial 22 
plus post-trial follow-up).  23 
Trials registration: clinicaltrials.gov. Identifier: NCT00671346  24 




The use of vitamin supplements is common. According to the National Health and Nutrition 2 
Examination Survey (2003-2006), half of the US population used at least one dietary 3 
supplement, 10% reported taking more than 5 dietary supplements and around 30% took 4 
supplements containing vitamin B12 or B6.1 For many nutrients, both too low and too high 5 
intakes may have adverse health consequences. According to randomized controlled trials 6 
(RCTs), high-dose vitamin supplementation may lead to unexpected side effects. For 7 
example, increased risk of lung cancer has been reported in men supplemented with beta 8 
carotene,2 supplementation with high doses of vitamin E may increase all-cause mortality3 9 
and contrary to expectation, increased risk of fracture in women have been reported in two 10 
randomized controlled trials after treatment with annual mega doses of vitamin D.4 5 Large 11 
homocysteine-lowering B-vitamin trials have failed to demonstrate prevention of 12 
cardiovascular diseases6 7 and cancer,8 9 and possible side effects have been reported.10 11  13 
 14 
Hip fractures constitute a major health problem in the elderly and are strongly associated with 15 
increased mortality and a burden for patients, the health care system and society.12 The 16 
expected rise in life expectancy in the global population will most probably lead to a 17 
substantial increase in the number of fractures and its consequences.13 The study and 18 
characterization of modifiable risk factors is essential for osteoporosis and fracture 19 
prevention. Several observational studies have showed an association between high levels of 20 
circulating total homocysteine (tHcy) and increased risk of osteoporosis and hip fracture.14 15 21 
In vitro studies have revealed possible mechanisms on how homocysteine may affect bone 22 
health by interfering with collagen cross linkage formation (reducing bone quality) and by 23 




Vitamin B12 and folate play important roles in the metabolism of homocysteine, being co-1 
factors for the methionine synthase enzyme. An increase in the concentration of these 2 
vitamins leads to a reduction in plasma tHcy levels.18 Observational studies have reported a 3 
small but significant inverse association between folate and vitamin B12 and fracture risk.15 19 4 
20 A possible direct effect of B-vitamins on bone physiology has also been investigated. 5 
Vitamin B6 is an essential co-factor for the enzyme lysyl oxidase, which is important for 6 
collagen cross-linking formation, and deficiency of vitamin B6 may lead to impaired cross-7 
linking formation.21 In vitro studies on a possible independent effect of folate and vitamin B12 8 
on bone structure are limited and their results are inconsistent.22 9 
 10 
Based on these premises, one RCT has been performed to evaluate a possible preventive 11 
effect of homocysteine-lowering treatment with B-vitamins on fracture incidence,23 and three 12 
have assessed fractures as secondary outcomes.24-26 However, results of these studies are 13 
inconclusive, and it is unlikely that new, large RCTs will be performed in order to establish 14 
the scientific basis for clinical advice on the use of B-vitamin supplements to prevent 15 
fractures. Hence, we utilized data from two Norwegian RCTs which were performed to assess 16 
the effect of intervention with high-dose oral B-vitamin treatment on cardiovascular disease,27 17 
28 to study whether there were any associations between the intervention with B-vitamins and 18 




 METHODS 2 
Participants and study intervention 3 
We combined data from two randomized, placebo-controlled, double-blind clinical trials 4 
performed in Norway: the Norwegian Vitamin Trial (NORVIT) (lasting from December 1998 5 
to March 2004) and the Western Norway B Vitamin Intervention Trial (WENBIT) (lasting 6 
from January 2000 to October 2005). Median in-trial follow-up was 3.4 years for NORVIT 7 
and 3.2 years for WENBIT. These trials had identical design, intervention, central laboratory 8 
and primary objective to determine if an intervention with folic acid, vitamin B12 and vitamin 9 
B6 could reduce cardiovascular morbidity and mortality in patients with ischemic heart 10 
disease. The objectives, design, and methods have been reported in more detail elsewhere,27 28 11 
and results from combined analyses of both studies have previously been reported concerning 12 
risk of cancer, cardiovascular diseases and total mortality.29 30 No benefit was found of folic 13 
acid plus vitamin B12 or vitamin B6  treatment on cardiovascular outcomes.  14 
In short, the studies had a two-by-two factorial design and patients were randomly assigned to 15 
1 of 4 different groups receiving one capsule per day containing: (1) folic acid (0.8 mg) plus 16 
vitamin B12 (cyanocobalamin, 0.4 mg) and vitamin B6 (pyridoxine hydrochloride, 40 mg) or 17 
(2) folic acid (0.8 mg) plus vitamin B12 (0.4 mg) or (3) vitamin B6 alone (40 mg) or (4) 18 
placebo. Blood samples were collected at baseline, at 1-2 months, and at the end of the 19 
intervention. They were analysed for serum creatinine, plasma homocysteine, serum 20 
cobalamin, serum folate and plasma pyridoxal 5’phospate  (PLP) as previously described.29 21 
  22 
Among baseline characteristics registered in the NORVIT and WENBIT trials, the following 23 
variables were considered of special relevance to the current study: age, gender, body mass 24 
index (BMI), smoking status, hypertension, (defined as medically treated) diabetes mellitus 25 
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(previously diagnose based on glucose levels) and presence of the 5,10-1 
methylenetetrahydrofolate reductase (MTHFR) gene (NCBI Entrez Gene 4524) 677 C-->T 2 
polymorphism (in which the TT genotype encodes for an enzyme with less activity, leading to 3 
increased tHcy).31 4 
 5 
Hip fracture ascertainment 6 
The combined dataset from the NORVIT and WENBIT trials was linked to new hip fractures 7 
in the NORHip database using the unique Norwegian 11 digit personal identification number 8 
in order to identify incident hip fractures among trial participants during follow-up. NORHip 9 
is a database including data on all patients with hip fractures treated at Norwegian hospitals 10 
from 1994 to 2013 extracted from the hospitals’ patient administrative systems. As described 11 
previously32 a new hip fracture in NORHip was identified in patients with a  diagnosis code 12 
for cervical, trochanteric or sub-trochanteric hip fracture (ICD-9: 820 with all subgroups; 13 
ICD-10: S72.0-S72.2) and a surgical procedure code indicating hip fracture surgery (98% of 14 
the fractures). A comprehensive algorithm was used to identify new hip fractures in cases 15 
with ambiguous information (classified as possible hip fractures) by taking surgical procedure 16 
codes, diagnosis codes and time between hospitalizations into account (around 2% of the 17 
fractures). The study outcome was defined as the first hip fracture sustained by a trial 18 
participant from inclusion throughout follow-up. If a person sustained more than one fracture 19 
during follow-up, only the first was included.  20 
 21 
Follow-up and statistical analyses 22 
Analyses were prepared and described on a blinded dataset (the variable giving information 23 
on which group each individual was randomized to was not included) and an analysis plan 24 
was agreed upon with a statistician not otherwise involved in our study (see supplementary 25 
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information: Analysis plan). The in-trial follow-up for each participant included the time from 1 
inclusion until the end of the intervention. To assess any long-term association, the extended 2 
follow-up (in-trial plus post-trial) lasted from the start of the trial until December 31st 2012. 3 
For both the in-trial and the extended follow-up, observation time was calculated from the 4 
date of inclusion until date of first hip fracture, date of death or end of follow-up. Date of 5 
death was obtained by linkage to the National Population Register.  6 
 7 
There were 43 hip fractures in the study population during the in-trial follow-up and 236 8 
during the extended follow-up. Based on these numbers a post-hoc calculation was 9 
performed: given that 50% of the participants were exposed to folic acid plus vitamin B12, the 10 
study had an 80% statistical power to find a relative risk of hip fracture of 0.39 at the 5% 11 
significance level during the in-trial follow-up, and a relative risk of 0.69 in the extended 12 
follow-up.  13 
 14 
Changes in serum or plasma markers from baseline until the end of intervention were tested 15 
with the paired sample t–test (only patients with serum or plasma measurements at both 16 
occasions were included in these analyses). 17 
 18 
Cumulative hazard curves were constructed by Cox proportional hazard regression, and 19 
differences between the groups were tested by the score test. Unadjusted hazard ratios (HR) 20 
with 95% Confidence Intervals (CI) were estimated by Cox proportional hazards regression 21 
stratified by trial. Adjusted HR’s were also calculated, adjusting for the following baseline 22 
characteristics: age (as a continuous variable), gender, BMI (as a continuous variable), 23 
smoking status, hypertension, diabetes mellitus and the MTHFR 677 CT polymorphism. 24 
We entered interaction terms to test if these variables interacted with the treatment modalities 25 
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on fracture risk. Proportional hazard assumption was tested using Schoenfeld residuals, and 1 
no violation of this assumption was detected.  2 
 3 
Subgroup analyses. 4 
The following six variables were dichotomized and displayed in forest-plots: gender, age 5 
which was dichotomized based on the median age of participants (62.5 years), trial 6 
(NORVIT/ WENBIT), smoking status (never smokers or ex-smokers >1 month vs. current 7 
smokers), MTHFR 677 CT polymorphism  (TT vs. CC or CT), plasma tHcy levels (based 8 
on a previous publication from the NORVIT study,27 high baseline tHcy was defined as 9 




No further patient contribution was required for the hip fracture follow-up. The study was 14 
approved by the Regional Committee for Medical and Health Research Ethics 15 










A total of 6837 participants were included in the analysis (see supplemental figure), 3749 3 
(54.8%) from NORVIT and 3090 (45.2%) from WENBIT. There were no substantial 4 
differences between the intervention groups in baseline characteristics (Table 1). Mean age of 5 
participants was 62.3 (±11.0) years, mean BMI was 26.6 (±3.8) and 23.5% were women. 6 
Thirty-nine per cent of the participants were current smokers, 10.6% had diabetes mellitus 7 
and 8.2% presented the MTHFR 677CT polymorphism. Only 22 (1.4%) women and 7 8 
(0.1%) men reported intake of osteoporosis medication at baseline. Median in-trial follow-up 9 
was 3.3 years (interquartile range 2.6-3.5 years), and 11.1 years (interquartile range 9.1-12.2 10 
years) for the extended follow-up. 11 
 12 
Vitamin and homocysteine levels during study treatment 13 
As previous published,29 mean concentration of plasma tHcy at baseline was 12.2 µmol/L 14 
(SD± 5.1). The reference range of homocysteine increases with age; for individuals older than 15 
59 years it should be lower than 12 µmol/L (5.8-11.9 µmol/L). Hyperhomocysteinemia is 16 
considered with values of tHcy>15 µmol/L. Deficit in vitamin B6 (PLP< 20 nmol/L)33 was 17 
found in 16.4% of the participants . Changes in circulating levels of the B-vitamins from 18 
baseline to the end of the intervention are shown in Table 2. Whereas participants receiving 19 
folic acid plus vitamin B12 had a substantial decrease in plasma tHcy and a substantial 20 
increase in serum folate and serum cobalamin, only minor changes in these parameters were 21 
found in those not receiving folic acid plus vitamin B12. Plasma PLP levels increased 22 
dramatically in both groups receiving intervention with vitamin B6, whereas minor changes 23 
were seen for those not receiving vitamin B6.  24 
10 
 
Table 1. Baseline characteristics of the NORVIT/WENBIT populationa 





Folic acid + 















NORVIT study, No. (%) 937 (54.9) 935 (54.9) 934 (54.8) 943 (54.8) 
WENBIT study, No. (%) 771 (45.1) 768 (45.1) 771 (45.2) 778 (45.2) 
Age, yb 62.7 ± 11.2 62.3 ± 10.9 62.0 ± 10.9 62.3 ± 10.7 
Gender male, No.(%) 1310 (76.7) 1313 (77.1) 1304 (76.5) 1300 (75.5) 
BMI,b,c 26.6 ± 3.9 26.5 ± 3.8 26.5 ± 3.7 26.7 ± 3.8 
Smoking status, (%)     
   Never smoker 488 (28.6) 514 (30.2) 449 (26.4) 487 (28.4) 
   Ex-smoker< 1 monthd 553 (32.4) 565 (33.2) 538 (31.6) 552 (32.2) 
   Current smoker 665 (39.0) 621 (36.5) 715 (42.0) 676 (39.4) 
Hypertension, yes (%) 627 (36.9) 605 (35.9) 615 (36.3) 643 (37.4) 
Diabetes mellitus, yes (%) 187 (11.0) 175 (10.3) 163 (9.6) 199 (11.6) 
Vitamin supplementse 401 (23.5) 398 (23.4) 390 (22.9) 392 (22.8) 
MTHFR 677 genotype, 
No./Total No. (%) 
    
  CC 806 (49.5) 862 (53.0) 810 (49.5) 816 (49.7) 
  CT 677 (41.6) 636 (39.1) 699 (42.7) 692 (42.1) 
  TT 144(8.9) 129 (7.9) 127 (7.8) 135 (8.2) 
Serum or plasma biochemical values 
Creatinineb, µmol/L 91.6 ± 23.0 90.8 ± 21.5 90.5 ± 21.4 91.6 ± 21.8 
Plasma total homocysteineb, 
µmol/L 
 
12.17 ± 4.82 
 
12.06 ± 4.69 
 
12.30 ± 5.60 
 
12.29 ± 5.06 
 
Serum cobalaminb 
(Vitamin B12), pmol/L 
 
384.31 ± 305.86 
 
387.20 ± 273.00 
 




Serum folateb, nmol/L 12.63 ± 21.04 12.18 ± 23.54 10.85 ± 7.87 10.85 ± 7.23 
Plasma pyridoxal 
5’phosphateb 
(Vitamin B6), nmol/L 
 
 
43.2  ± 44.0 
 
 
38.5 ± 29.3 
 
 
43.5 ± 44.3 
 
 
39.3 ± 35.5 
 
Abbreviations: BMI, Body mass index, MTHFR, 5,10-methylenetetrahydrofolate reductase; NORVIT, the 
Norwegian Vitamin Trial; WENBIT, the Western Norway B Vitamin Intervention Trial. 
aInformation available for 6827 participants with BMI, 6823 with smoking status, 6796 with hypertension status, 
6808 with Diabetes mellitus status, 6533 with MTHFR 677 genotype (out of a total of 6837 participants). 
bValues are expressed as mean ±  standard deviation. 
cBMI was calculated as weight in kilograms divided by height in meters squared. 
dDefined as: participant quit smoking more than 1 month before trial entry. 




Table 2. Circulating homocysteine and B-vitamins during the trialsa 
 Baseline End of study Change  
 Mean ± SDb Mean ± SDb Mean ± SDb       P c 
 
Plasma total homocysteine, µmol/L 
Folic acid + 
Vitamin B12 + Vitamin B6      
n= 1385 
11.82 ± 4.27 8.84 ± 3.22 -2.97 ± 3.76 <0.001 
Folic acid + Vitamin B12 
n= 1417 
11.95 ± 4.72 9.13 ± 3.71 -2.82 ±4.57 <0.001 
Vitamin B6 
n= 1373 
12.05 ± 5.19 12.25 ± 5.04 0.20 ± 4.65 0.127 
Placebo 
n= 1400 
11.97 ± 4.60 12.42 ± 5.26 0.46 ± 4.61 <0.001 
 
Serum cobalamin (Vitamin B12), pmol/L 
Folic acid + 
Vitamin B12 + Vitamin B6      
n=1376 
380.54 ± 167.48 610.66 ± 324.54 230.12 ± 299.13 <0.001 
Folic acid + Vitamin B12 
n= 1405 
386.02 ± 268.32 626.76 ± 488.01 240.75 ± 430.86 <0.001 
Vitamin B6 
n= 1364 
388.69 ± 509.68 381.56 ± 274.39 -7.13 ± 502.70 0.600 
Placebo 
n= 1385  
376.14 ± 216.21 379.21 ±223.51 3.07 ± 178.43 0.522 
 
Serum folate, nmol/L 
Folic acid + 
Vitamin B12 + Vitamin B6   
n= 1378   
12.13 ± 17.88 59.35 ± 31.84 47.22 ± 34.81 <0.001 
Folic acid + Vitamin B12 
n= 1411 
12.34 ± 25.29 66.21 ± 36.89 53.87 ± 44.11 <0.001 
Vitamin B6 
n=1362 
10.94 ± 7.77 11.40 ± 11.10 0.45 ± 11.99 0.162 
Placebo 
n= 1388 
10.84 ± 7.10 13.81 ± 14.08 2.97± 13.86 <0.001 
 
Plasma pyridoxal 5’phosphate (Vitamin B6), nmol/L 
Folic acid+ 
Vitamin B12 + Vitamin B6     
n=1366 
42.54 ± 39.37 292.35 ± 175.54 249.81 ± 176.17 <0.001 
Folic acid + Vitamin B12 
n= 1397 
38.66 ± 28.47 47.01 ± 42.36 8.34 ± 45.78 <0.001 
Vitamin B6 
n= 1366 
44.13 ± 44.05 289.90 ± 176.67 245.77 ± 177.40 <0.001 
Placebo 
n= 1378 
40.07 ± 36.88 48.11 ± 41.63 8.04 ± 49.23 <0.001 
 
a Patients with data both at the beginning and at the end of the intervention. 
b Values are expressed as mean ±  standard deviation. 










Table 3. Baseline characteristics of the NORVIT/WENBIT population based on sustaining vs. 



















NORVIT, No. (%) 152 (64.4) 3,597 (54.4)  




71.4 ± 8.4 
 














24.7 ± 3.6 
 




Smoking status, yes (%) 
  
0.05 
Never smoker  93 (39.4)  1,845 (28.0)  
Ex-smoker >1 monthe 65 (27.5) 2,144 (32.6)  
Current smoker 78 (33.1) 2,592 (39.4)  
 
















MTHFR 677 CT 
polymorphism,  











Serum or plasma biochemical values 
Creatinine, (No.) µmol/Lc (236) 93.2 ± 29.1 (6,603) 91.0 ± 21.6 0.13 
Homocysteine, (No.) µmol/Lc (235) 13.6 ± 5.2 (6,581) 12.2 ± 5.0 <0.01 
Cobalamin, (No.) pmol/Lc (234) 431.5 ± 517.6 (6,517) 382.9 ± 320.8 0.02 
Folate, (No.) nmol/Lc (233) 11.3 ± 8.3 (6,542) 11.6 ± 16.9 0.70 
Pyridoxal 5’phosphate,  
(No.) nmol/Lc 
 
(233) 35.1 ± 30.0 
 





Abbreviations: BMI, Body mass index, MTHFR, 5,10-methylenetetrahydrofolate reductase; NORVIT, the Norwegian Vitamin 
Trial; WENBIT, the Western Norway B Vitamin Intervention Trial. 
aBecause of rounding, percentages may not total 100. 
bFor interaction between variables (differences were tested by using a chi-square test for categorical variables, and t-test 
for continuous variables). 
cValues are expressed as mean ±  standard deviation. 
dBMI was calculated as weight in kilograms divided by height in meters squared. 




A total of 43 patients (28 women) suffered a hip fracture during the in-trial follow-up, and 2 
236 (118 women) during the extended follow-up. For baseline characteristics of those 3 
suffering a hip fracture, see Table 3.  4 
As shown in Table 4 and figure 1 there were no significant differences in the risk of hip 5 
fracture between the intervention groups receiving folic acid plus vitamin B12 versus the 6 
groups not receiving it, with a HR of 0.87 (95%CI 0.48-1.59) during the in-trial follow-up, 7 
and a HR of 1.08 (95% CI 0.84-1.40) during the extended follow-up. No material differences 8 
were found in the results after adjusting for baseline characteristics (data not shown). 9 
 10 
On the other hand, there was a statistically significant 42% (95% CI 9%-83%) increased risk 11 
of hip fracture in the groups receiving vitamin B6 compared with groups not receiving vitamin 12 
B6 during the extended follow-up. The corresponding p-value for the score test was 0.008 13 
(Figure 2). For the in-trial follow-up, there was a non-significant association with a HR of 14 
1.42 (95% CI 0.78-2.61). Adjusting for baseline characteristics did not change the results 15 
substantially (data not shown). 16 
 17 
Considering the four treatment groups separately, the incidence rate of hip fracture throughout 18 
the extended follow-up was highest in the group receiving both folic acid + vitamin B12 and 19 
vitamin B6, followed by the group receiving vitamin B6 alone (Table 4). Additional analyses 20 
showed that the group receiving treatment with folic acid plus vitamin B12 and vitamin B6 had 21 
a statistically significant higher fracture risk compared to the placebo group (HR 1.49; 95%CI 22 




Table 4.  Hip fracture rates according to randomization groups and Hazard Ratios (HR) of hip fracture with 95% confidence interval (CI) according to folic acid 
vs. no folic acid treatment groups and vitamin B6 versus no vitamin B6 treatment groups.a 
 
  Number of Fractures  
(Rates per 1000 Observation-Years) 
 




Folic Acid + 
Vitamin B12 and 
Vitamin B6 
Folic Acid + 
Vitamin B12 
Vitamin B6 Placebo Folic Acid+Vitamin B12 vs. 
Non-Folic Acid+Vitamin B12 
Groups 


















Abbreviations: CI, confidence interval.  
aAll models are stratified by trial (NORVIT or WENBIT). 
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There were no statistically significant differences between each of the other two groups 
compared with placebo for the risk of hip fracture, with a HR =0.89, 95% CI (0.60-1.32) for 
the group receiving folic acid plus vitamin B12 and a HR= 1.19, 95% CI (0.83-1.72) for the 
group receiving vitamin B6. However, the interaction term between the two treatment regimes 
and risk of hip fracture was not statistically significant (p= 0.20). 
 
Stratified analyses 
Overall, the interaction terms between the treatment modalities and relevant baseline 
characteristics were not statistically significant, indicating no effect modification (Figure 3 
and 4). The only exception was a statistically significant interaction between gender and the 
folic acid plus vitamin B12 treatment (Figure 3; p value for interaction = 0.027). Women, but 
not men, receiving folic acid plus B12 had a statistically significant increased risk of fracture.  
To explore this further, we analysed the four intervention groups separately. Compared to 
placebo (reference group), women receiving both B vitamin treatments (folic acid plus 
vitamin B12 and vitamin B6) had a HR=1.87 (95% CI 1.14-3.07), whereas women receiving 
folic acid plus vitamin B12 had a HR=1.13 (95% CI 0.65-1.95) and women receiving vitamin 
B6 alone had a HR=1.03 (95% CI 0.59-1.80) of sustaining a hip fracture. A similar analysis in 
men showed no significant associations (data not shown). 
 
Sensitivity analyses 
Six of the 236 participants who suffered a hip fracture during follow-up had a previous hip 
fracture before the trials started. Excluding these participants from the analyses did not 
change the results substantially (data not shown). In addition, five of the included hip 
fractures were classified as possible hip fractures in NORHip database. Sensitivity analyses 




This study showed that treatment with folic acid plus vitamin B12 in a population with 
ischemic heart disease during a mean of 3.0 years was not associated with the risk of hip 
fracture neither during in trial nor during an extended follow-up period (mean 10.0 years). 
Treatment with vitamin B6 was associated with an increased risk of hip fracture during the 
extended follow-up. However no statistical significant association was found for this 
treatment during the in-trial follow-up. 
Strengths and limitations 
A main strength of our study was the use of two large and well-designed RCTs with nearly 
7,000 participants. We were able to follow the participants with respect to hip fracture by 
linkage to the national NORHip database covering the complete Norwegian population. These 
RCTs were performed in Norway, where there is no mandatory folic acid fortification of 
foods.34 The decrease in tHcy plasma levels due to the folic acid plus vitamin B12 intervention 
in NORVIT/WENBIT trials was thus more pronounced than in trials performed in countries 
where such fortification is recommended or mandatory. As reported previously, participants 
showed high adherence to the treatment, assessed by interview, capsule count and 
corroborated by substantial changes in circulating concentrations of B-vitamins and tHcy 
during in-trial follow-up.29 We do not know whether patients were taking vitamin 
supplements during the post-trial follow-up period. However, it is unlikely that they 
consumed the high doses used in the trials, because patients were discouraged from such 
supplement use when trial results from NORVIT and WENBIT were available. Further, we 
assume that post-trial B-vitamin doses were moderate, since the doses of B-vitamins in over-
the-counter supplements in Norway are far lower than the doses given in the two trials. 
Finally, we believe that there were similar proportions of B-vitamin supplement users across 
initial treatment groups.  
17 
 
It is a limitation that neither NORVIT nor WENBIT were originally designed or powered to 
study hip fractures. Hence, the registered baseline data did not include bone related variables 
like bone mineral density, bone markers or data on falls which could have helped assessing 
possible mechanisms for the increased fracture risk. Nevertheless, a similar distribution of 
these parameters among the treatment groups is expended due to the randomized allocation of 
participants to the intervention groups. Information about hip fractures was registry-based, 
and the individual fracture was not verified by medical record review. However, a previous 
validation of the NORHip database showed good agreement with medical chart and x-ray 
verified hip fractures (Cohen`s kappa = 0.95).35 In other words, the possibility of a 
misclassification of a hip fracture diagnosis is low, and due to the design of the study they 
would be randomly distributed. We had no information of emigration in the current dataset. 
Nevertheless, based on a previous publication29 it was less than 0.8% during a median of 6.5 
years, so it is quite unlikely that it would have an impact in our results.  
It is a limitation that the trials were performed among patients with ischemic heart disease. 
Thus, the generalizability of our findings must be interpreted with caution. On the other hand, 
ischemic heart disease and its treatments are common in the elderly. In addition, the study 
population was rather young with respect to the hip fracture outcome, and only 23% of the 
participants were women. It would be worth confirming our results in an older population 
with a higher female ratio and also to study other types of fracture. 
 
The increased risk of hip fracture in those receiving vitamin B6 was an unexpected finding, 
and we cannot exclude a spurious association. It is also puzzling that the association was 
evident years after the intervention had stopped. On the other hand, our analyses were based 
on two well-designed RCTs where recall bias and confounding were controlled for. We also 
performed additional analyses adjusting for possible confounders, outcome data was obtained 
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from a validated database (NORHip), and the research questions (see Analyses plan in 
additional information) were described before the analyses started.  
Comparison with other studies 
Regarding treatment with folic acid and vitamin B12, the results of our study are in accordance 
with previous large RCTs that have failed to identify any significant association between folic 
acid plus vitamin B12 treatment and the incidence of osteoporotic fractures.24-26 These RCTs, 
as the case is for the current study, were not designed to study fractures as the main outcome 
except for the Dutch B-PROOF (B-vitamin for the Prevention Of Osteoporotic fractures)23 
study. The B-PROOF study showed no effect of homocysteine lowering treatment on fracture 
incidence. Only in a pre-specified subgroup analysis among those older than 80 years, the 
intervention group had lower risk of osteoporotic fractures. 
Although all of these RCTs presented differences in design and study population, they 
reached similar overall conclusions of no association between the intervention with folic acid 
and vitamin B12 and fractures. It could be added that a publication reporting that an 
intervention with folic acid plus vitamin B12 reduced the risk of hip fracture in patients with 
stroke has recently been retracted by the editors of JAMA.36  
 
To the best of our knowledge, no RCT has been performed to assess the effect of vitamin B6 
alone  on hip fracture risk. The HOPE-226 and VITATOPS25 trials included vitamin B6 as part 
of their intervention. However, due to their design based on a combined intervention, 
assessing the association between vitamin B6 alone and fracture incidence was not possible. In 
addition, the number of hip fractures in VITATOPS was limited to 70, and the number of hip 
fractures in HOPE-2 has not been reported. Observational studies on vitamin B6 and fracture 
risk are limited. Although results so far may relate low vitamin B6 intake to higher risk of hip 




We can only speculate on possible mechanistic explanations for the increased fracture risk 
association with vitamin B6 treatment. Of potential relevance is the fact that the vitamin B6 
dose of 40 mg/d used in our trials was substantially higher than the Recommended Dietary 
Allowances (1.3-1.7 mg, depending on adult age) and could be considered as a pharmacologic 
dose much higher than the average dietary intake (1.5 mg/day in women and 2 mg/day in 
men).39 40 Tolerable upper daily intake has been set to 25 mg by the European Food Safety 
Authority (year 2000)41 and to 100 mg by the US Food and Nutrition Board.40 Ataxia, 
neuropathy and decreased muscle tone have been described as side effects of high daily doses 
of vitamin B6 (500 mg or more),42 although minor neurological symptoms have been 
described with a dose of 50 mg daily.43 The neurological damage may cause numbness, 
instability and troubled walking leading to higher possibilities of falling. The neurological 
effect appears to be dose and time dependent, but there is not adequate evidence concerning a 
total improvement of functions after discontinuing treatment.44  
As a second possibility, vitamin B6 has been suggested as a modulator of steroid receptors, 
reducing receptors response in the presence of high vitamin B6 concentrations.45 46However  
molecular basis of this effect are still unclear. However, in case high doses have such an 
effect, it is unlikely that participants would regain the bone mass they had lost after the 
treatment has ended, potentially leading to a long lasting effect. 
 
Common etiological factors have been suggested for cardiovascular diseases and 
osteoporosis. However, B-vitamin treatment (either with the folic acid plus vitamin B12 
intervention or vitamin B6 intervention) had no effect on cardiovascular events in the original 
analysis of NORVIT and WENBIT, in contrast to the long-term association between vitamin 
B6 treatment and hip fracture in the current analysis.  
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It should be noted that in the additional analysis of the four intervention groups separately, the 
group receiving both treatments (folic acid plus vitamin B12  and vitamin B6) had the highest 
risk of hip fracture. These results are somewhat in line with the results from NORVIT, where 
the participants who received B-vitamin combination therapy had an increased risk of 
cardiovascular events.27 As for vitamin B6, the dose of vitamin B12 was also much higher than 
the Recommended Dietary Allowances (400 mcg versus 2.4 mcg). However, we can not 
conclude that the association with hip fracture was different for the intervention with folic 
acid plus vitamin B12 and vitamin B6 compared to the intervention with vitamin B6 alone, as 
the interaction term between the two treatments and hip fractures was not statistically 
significant. On the other hand, the statistical power to detect such a difference was low.  
Possible implications  
Dietary supplements of vitamins and minerals are extensively available in a wide range of 
doses and combinations. In segments of the population, high dose vitamin supplementation 
far exceeding the recommended doses is popular with promise of health benefits and very 
little focus on potential side effects. Our findings have potential public health implications, 
mainly related to the need to respect the daily dosage recommendations when there is no 
deficiency of these vitamins. Use of supplements with high doses of vitamins could result in 
unexpected deleterious side effects for the individual. 
Conclusion 
These secondary analyses and extended follow-up of two large randomized controlled trials 
performed in Norway showed that treatment with folic acid plus vitamin B12 was not 
associated with the risk of hip fracture. However, treatment with high doses of vitamin B6 was 
associated with a slightly increased risk of experiencing a hip fracture during the extended 






Figure 1. Cumulative hazard curves for hip fracture. Comparisons were performed between 
folic acid versus no folic acid treatment groups.  
Figure 2. Cumulative hazard curves for hip fracture. Comparisons were performed between 
vitamin B6 and no vitamin B6 treatment groups.  
Figure 3. Hazard ratios for sustaining a hip fracture in subgroups, and p values for interaction 
(P). The comparisons were performed for the extended follow-up (from randomization to 31 
December 2013) between folic acid and no folic acid treatment groups. 
Figure 4. Hazard ratios for sustaining a hip fracture in subgroups, and p values for interaction 
(P). The comparisons were performed for the extended follow-up (from randomization to 31 
December 2013) and between vitamin B6 and no vitamin B6 treatment groups.  
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Figure 1. Cumulative hazard curves for hip fracture. Comparisons were performed between 























Figure 2. Cumulative hazard curves for hip fracture. Comparisons were performed between 


















Figure 3. Hazard ratios for sustaining a hip fracture in subgroups, and p values for interaction 
(P). The comparisons were performed for the extended follow-up (from randomization to 31 






















Figure 4. Hazard ratios for sustaining a hip fracture in subgroups, and p values for interaction 
(P). The comparisons were performed for the extended follow-up (from randomization to 31 
December 2013) and between vitamin B6 and no vitamin B6 treatment groups.  
 
 
 
 
